Allopurinol in Acute Gout

This study has been withdrawn prior to enrollment.
(because of a lack of funding)
Sponsor:
Information provided by (Responsible Party):
Artur de Brum-Fernandes, Université de Sherbrooke
ClinicalTrials.gov Identifier:
NCT01775098
First received: January 21, 2013
Last updated: December 10, 2013
Last verified: December 2013
  Purpose
The objectives of the present study are to determine if starting treatement of hyperuricemia with allopurinol during an acute gout crises has an impact on the duration or the severity of the crises

Condition Intervention
Gout
Drug: allopurinol

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Allopurinol in Acute Gout

Resource links provided by NLM:


Further study details as provided by Université de Sherbrooke:

Primary Outcome Measures:
  • Duration of the gout crises [ Time Frame: First 7 days after visit ] [ Designated as safety issue: No ]
    Presence of inflammatory signs


Enrollment: 0
Study Completion Date: February 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Allopurinol
treatment with allopurinol
Drug: allopurinol
Placebo Comparator: placebo
placebo comparator

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

More than 18 years old Able to sign informed consent Indication of long-term treatment with allopurinol Acute gout crisis

Exclusion Criteria:

Les than 18 years-old Unable to consent Contra-indication to allopurinol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

Responsible Party: Artur de Brum-Fernandes, Doctor, Université de Sherbrooke
ClinicalTrials.gov Identifier: NCT01775098     History of Changes
Other Study ID Numbers: Allopurinol in acute gout 
Study First Received: January 21, 2013
Last Updated: December 10, 2013
Health Authority: Canada: Health Canada

Keywords provided by Université de Sherbrooke:
Gout
uric acid
allopurinol

Additional relevant MeSH terms:
Gout
Arthritis
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Purine-Pyrimidine Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases
Allopurinol
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Antioxidants
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on August 23, 2016